Antiretroviral treatment simplification witih nevirapine in protease-inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study

Article Abstract:

Switching AIDS therapy from a combination of drugs that includes a protease inhibitor to one that includes nevirapine may benefit HIV patients with fat metabolism disorders caused by protease inhibitors. In a study of 106 HIV patients who switched, cholesterol levels decreased, but changes in body composition remained the same.

Prognosis, Lipid metabolism disorders, Lipidosis, Nevirapine

---

Alternation of antiretroviral drug regimens for HIV infection: a randomized, controlled trial

Article Abstract:

Background: Mathematical modeling has suggested that alternating antiretroviral regimens while patients' viral load remains suppressed would minimize HIV resistance mutations. Objective: To compare alternation of antiretroviral regimens with the current standard of switching regimens after viral load rebound. Design: Randomized, multicenter, open-label, pilot trial. Setting: 15 outpatient HIV clinics in Spain and Argentina. Patients: 161 HIV-1-infected, antiretroviral-naive persons. Intervention: Patients were assigned to continuously receive stavudine, didanosine, and efavirenz (standard of care, regimen A) or zidovudine, lamivudine, and nelfinavir (standard of care, regimen B) until virologic failure, or to alternate between those two regimens every 3 months while viral load was suppressed (regimen C). Measurements: Time to virologic failure, percentage of patients with undetectable plasma viremia over 48 weeks, CD4 and CD8 cell counts, adverse events, emergence of drug resistance, drug adherence, and quality of life. Results: Patients receiving standard-of-care regimens A and B did not differ. Virologic failure over 48 weeks was delayed in the alternating therapy group compared with the pooled standard-of-care group (incidence rate, 1.2 events/1000 person-weeks [95% CI, 0.3 to 3.6 events/1000 person-weeks] vs. 4.8 events/1000 person-weeks [CI, 2.9 to 7.4 events/1000 person-weeks]; P=0.01). Genotypic drug resistance emerged in 79% of patients in the standard-of-care group who experienced on-therapy treatment failure. Patients in the standard-of-care and alternating therapy groups had similar CD4 cell counts, frequency of adverse events, reported drug adherence, and quality of life. Conclusions: Virologic outcome was better with alternating therapy than with the current standard of care, while adverse events and adherence were similar. The strategy of alternating therapy merits further investigation.

Prevention, Drug resistance in microorganisms, Microbial drug resistance, Author Abstract

---

Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients

Article Abstract:

Indinavir appears to produce sustained viral load suppression in some HIV patients who have not adequately responded to therapy with reverse transcriptase (RT) inhibitor drugs. Doctors treated 25 HIV patients with indinavir in addition to previously prescribed RT drugs for 24 weeks. Fifty-six percent of patients had a sustained reduction in viral load, most to undetectable levels. Patients without a favorable response to indinavir were either infected with a drug-resistant strain of HIV, or failed to take the medication as directed.

Health aspects, Indinavir, Protease inhibitors, Drug therapy, Combination, Combination drug therapy

Similar abstracts:

• Abstracts: Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study
• Abstracts: Effect of prenatal and infancy home visitation by nurses on pregnancy outcomes, childhood injuries, and repeated childbearing: a randomized controlled trial
• Abstracts: Use of continous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial
• Abstracts: Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial
• Abstracts: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.